Ichikawa M, Suzuki H, Kumagai K, Kumagai H, Ryuzaki M, Nishizawa M, Saruta T
Department of Internal Medicine, Keio University, School of Medicine, Tokyo, Japan.
Hypertension. 1995 Sep;26(3):425-31. doi: 10.1161/01.hyp.26.3.425.
We investigated the effects of long-term oral treatment with four different classes of antihypertensive drugs (a thiazide diuretic [trichlormethiazide, 10 mg/kg per day]; a beta-blocker [atenolol, 90 mg/kg per day]; a calcium channel antagonist [nicardipine, 150 mg/kg per day]; and an angiotensin-converting enzyme inhibitor [enalapril maleate, 10 mg/kg per day]) on aortic baroreceptor activity in spontaneously hypertensive rats with chronic hypertension (36 weeks of age). Treatment with each of the four drugs, given from 10 to 36 weeks of age, similarly decreased arterial pressure (171 +/- 2 to 144 +/- 1 mm Hg, P < .01) and similarly decreased the threshold pressure for baroreceptors (116 +/- 3 to 103 +/- 1 mm Hg, P < .05). The four antihypertensive drugs also potentiated the maximal gain of the pressure-activity relation in these rats (untreated, 1.08 +/- 0.05% maximum/mm Hg); however, nicardipine and enalapril (1.77 +/- 0.04% and 1.70 +/- 0.06% maximum/mm Hg, respectively) augmented the maximal gain to a greater extent (P < .05 to .01) than did trichlormethiazide or atenolol (1.49 +/- 0.05% and 1.42 +/- 0.02% maximum/mm Hg, respectively). When the initiation of treatment was delayed to 28 weeks of age, no differences were found in the effects on either threshold pressure (104 +/- 1 mm Hg) or maximal gain (1.36 +/- 0.03% maximum/mm Hg) for all four drugs.(ABSTRACT TRUNCATED AT 250 WORDS)
我们研究了四类不同的抗高血压药物(一种噻嗪类利尿剂[三氯噻嗪,每天10毫克/千克];一种β受体阻滞剂[阿替洛尔,每天90毫克/千克];一种钙通道拮抗剂[尼卡地平,每天150毫克/千克];以及一种血管紧张素转换酶抑制剂[马来酸依那普利,每天10毫克/千克])长期口服给药对患有慢性高血压(36周龄)的自发性高血压大鼠主动脉压力感受器活动的影响。从10周龄至36周龄给予这四种药物中的每一种进行治疗,同样降低了动脉血压(从171±2降至144±1毫米汞柱,P<.01),并且同样降低了压力感受器的阈值压力(从116±3降至103±1毫米汞柱,P<.05)。这四种抗高血压药物还增强了这些大鼠压力-活动关系的最大增益(未治疗组为1.08±0.05%最大反应/毫米汞柱);然而,尼卡地平和依那普利(分别为1.77±0.04%和1.70±0.06%最大反应/毫米汞柱)比三氯噻嗪或阿替洛尔(分别为1.49±0.05%和1.42±0.02%最大反应/毫米汞柱)更大程度地增强了最大增益(P<.05至.01)。当治疗开始推迟至28周龄时,发现这四种药物对阈值压力(104±1毫米汞柱)或最大增益(1.36±0.03%最大反应/毫米汞柱)的影响没有差异。(摘要截短于250字)